JPMorgan analyst Chris Schott raised the Eli Lilly price target to $1,400. The previous target was $1,300. Schott reiterated an Overweight rating for the company.
The firm expects sustained global demand for obesity and diabetes treatments Mounjaro and Zepbound. Eli Lilly shares trade near all-time highs as market capitalization exceeds $1 trillion.
The company’s incretin franchise drove a 55.5% year-over-year revenue increase. This growth was recorded in the first quarter of 2026.